EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study

Birgitta Salmela iD, Jussi Jaakkola iD, Ksenia Kalatsova iD, Jaakko Inkovaara iD, Aapo L Aro iD, Konsta Teppo iD, Tero Penttilä iD, Olli Halminen iD, Jari Haukka iD, Jukka Putaala iD, Miika Linna iD, Pirjo Mustonen iD und 3 weitere

Europace · 2024

DOI: 10.1093/europace/euae264 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Europace, 2024. Verfasst von Birgitta Salmela und 14 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center, Department of Internal Medicine, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, Finland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anti-Arrhythmia Agents, Registries, Catheter Ablation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Aarne Koskelo Foundation, Finnish Foundation for Cardiovascular Research, Helsinki and Uusimaa Hospital District research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Atrial fibrillation (AF) patients frequently require active rhythm control therapy to maintain sinus rhythm and reduce symptom burden. Our study assessed whether antiarrhythmic therapies (AATs) are used disproportionately between men and women after new-onset AF. Methods and results The nationwide Finnish anticoagulation in AF registry-based linkage study covers all patients with new-onset AF in Finland during 2007–2018. Study outcomes included initiation of AATs in the form of antiarrhythmic drugs (AADs), cardioversion, or catheter ablation. The study population constituted of 229 565 patients (50% females). Women were older than men (76.6 ± 11.8 vs. 68.9 ± 13.4 years) and had higher prevalence of hypertension or hyperthyroidism, but lower prevalence of vascular disease, diabetes, renal disease, and cardiomyopathies than men. Overall, 17.6% of women and 25.1% of men were treated with any AAT. Women were treated with AADs more often than men in all age groups [adjusted subdistribution hazard ratio (aSHR) 1.223, 95% confidence interval (CI) 1.187–1.261]. Cardioversions were also performed less often on women than on men aged <65 years (aSHR 0.722, 95% CI 0.695–0.749), more often in patients ≥ 75 years (aSHR 1.166, 95% CI 1.108–1.227), while no difference between the sexes existed in patients aged 65–74 years. Ablations were performed less often in women aged <65 years (aSHR 0.908, 95% CI 0.826–0.998) and ≥75 years (aSHR 0.521, 95% CI 0.354–0.766), whereas there was no difference in patients aged 65–74 years.

Conclusion

Women used more AAD than men in all age groups but underwent fewer cardioversion and ablation procedures when aged <65 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnti-Arrhythmia AgentsRegistriesCatheter AblationHumansFemaleMaleAgedFinlandMiddle AgedSex FactorsAge FactorsAged, 80 and overElectric CountershockHealthcare DisparitiesRisk FactorsPractice Patterns, Physicians'

Stichwörter der Autor:innen

AblationAntiarrhythmic drugsAtrial fibrillationCardioversionRhythm controlSex difference

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Heart Center, Department of Internal Medicine, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, Finland.
  • Heart Centre, Turku University Hospital and University of Turku, Turku, Finland.
  • Faculty of Medicine,University of Helsinki, Helsinki, Finland.
  • Tays Heart Hospital, Tampere University Hospital, Tampere, Finland.
  • Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Department of Industrial Engineering and Management, Aalto University, Espoo, Finland.

ORCID-Profile: Birgitta Salmela, Jussi Jaakkola, Ksenia Kalatsova, Jaakko Inkovaara, Aapo L Aro, Konsta Teppo, Tero Penttilä, Olli Halminen, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Juha Hartikainen, K E Juhani Airaksinen, Mika Lehto

Förderung

  • Aarne Koskelo Foundation
  • Finnish Foundation for Cardiovascular Research
  • Helsinki and Uusimaa Hospital District research

Zitieren

APA

Salmela, B., Jaakkola, J., Kalatsova, K., Inkovaara, J., Aro, A. L., Teppo, K., Penttilä, T., Halminen, O., Haukka, J., Putaala, J., Linna, M., Mustonen, P., Hartikainen, J., Airaksinen, K. E. J., & Lehto, M. (2024). Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study. Europace. https://doi.org/10.1093/europace/euae264

Vancouver

Salmela B, Jaakkola J, Kalatsova K, Inkovaara J, Aro AL, Teppo K, et al. Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study. Europace. 2024. doi:10.1093/europace/euae264

BibTeX
@article{Salmela2024,
  author = {Salmela, Birgitta and Jaakkola, Jussi and Kalatsova, Ksenia and Inkovaara, Jaakko and Aro, Aapo L and Teppo, Konsta and Penttilä, Tero and Halminen, Olli and Haukka, Jari and Putaala, Jukka and Linna, Miika and Mustonen, Pirjo and Hartikainen, Juha and Airaksinen, K E Juhani and Lehto, Mika},
  title = {Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study},
  journal = {Europace},
  year = {2024},
  doi = {10.1093/europace/euae264}
}
Kostenlos starten →